

Lung Cancer: where we are? Fourth Edition

07.04.2026

IRST IRCCS “Dino Amadori” - Meldola

Scientific Chairs: Dott. Delmonte, Dott. Normanno, Dott. Parisi, Prof. Crinò

8.30 Registration

9.00 Introduction from the Scientific and General Directors and from Scientific Chairs

1 SESSION

Early stage and locally advanced non small-cell lung cancer

Chairs: Dott. Elisabetta Parisi, Dott. Antonino Romeo

9.15 Screening update in Europe in lung cancer – Dott. Ugo Pastorino, Milano

9.30 Preroperative staging for NSCLC - Prof. Venerino Poletti, Forlì

9.45 Surgery after neoadjuvant chemo-immunotherapy: more difficulties and how to overtake them – Dott. Desideria Argnani, Forlì

10.00 Neoadjuvant approaches in early stages, non oncogene addicted NSCLC: how to choose between pre and peri operative approach – Prof. Andrea Ardizzoni, Bologna

10.15 Adjuvant approaches in early stages: an evolving landscape - Prof. Francesco Passiglia, Orbassano

10.30 Stage IIIB unresectable, locally advanced NSCLC – Prof. Marcello Tiseo, Modena

10.45 Radiotherapy as an alternative to surgery in early stage NSCLC – Prof. Andrea Filippi, INT

11.00 Discussion

11.15 Coffee break

2 SESSION

Oncogene addicted, advanced diseases

Chairs: Dott. Paola Ulivi, Prof. Lucio Crinò

- 11.30 **Sex and gender in lung cancer: which role?** – Prof. Rossana Berardi, Ancona
- 11.45 **Liquid biopsy in lung cancer: where are we?** – Prof. Umberto Malapelle, Napoli
- 12.00 **EGFR mutants: different therapies for different tumors** – Dott. Antonio Passaro, Milan
- 12.15 **KRAS oncogene addicted tumors** - Prof. Diego Cortinovis, Milan
- 12.30 **Rare oncogene addicted tumors (ALK, ROS1, BRAF, RET, MET, NTRK, HER2)** – Dott. Kalliopi Andrikou, IRST
- 12.45 **Antibody Conjugates in lung cancer** - Dott. Francesca Fusco, Milano
- 13.00 **Discussion**
- 13.15 **Light Lunch**

3 SESSION

Advanced non-oncogene driven diseases

Chairs: Dott. Chiara Bennati, Dott. Angelo Delmonte

- 14.15 **Artificial Intelligence in lung cancer** – Dott. Laura Mazzeo, Milan
- 14.30 **Immunotherapy in NSCLC: how to use it** – Dott. Rita Chiari, Pesaro
- 14.45 **Mechanism of Resistance to immunocheckpoint inhibitors** – Dott. Giuseppe Lamberti, Bologna
- 15.00 **New ways in immunotherapy** – Prof. Sara Pilotto, Verona
- 15.15 **Phase 1 clinical trial: advantages and limits in NSCLC** – Prof. Marco Filetti, Roma
- 15.30 **Discussion**

4 SESSION

Rare Thoracic Cancers

Chairs: Dott. Davide Tassinari, Dott. Angelo Delmonte

- 15.45 **Tumors of the Thymus: future perspectives** – Dott. Tommaso Martino De Pas, Bergamo
- 16.00 **Small Cell Lung Cancer: state of the art for local and extended disease** - Dott. Alberto Verlicchi,
IRST

16.15 **Small Cell Lung Cancer: new therapeutic options** – Dott. Federica Bertolini, Modena

16.30 **Pleural mesothelioma: a new landscape?** – Prof. Luana Calabrò, Ferrara

16.45 **Discussion**

17.00 **Conclusions**

RATIONALE

Lung cancer is the first cause of death for tumors worldwide.

However several improvements have been obtained mainly due to the increased biologic knowledge.

In fact today with the term lung cancer we consider a group of several diseases, distinguished according to histology and molecular features.

These aspects are fundamental in order to define the most active therapeutic strategies.

This landscape is rapidly evolving and every year new data are available.

So far it is particularly important to have the possibility to discuss the new data together with outstanding experts in order to improve the knowledge for a better cure for patients.

Acronimi:

NSCLC - carcinoma polmonare non a piccole cellule

EGFR - Estimated Glomerular Filtration Rate

KRAS - Kirsten Rat Sarcoma Viral Oncogene Homolog

ALK - Anaplastic Lymphoma Kinase

ROS1 - proto-oncogene 1, recettore tirosin-chinasi

BRAF - B-Raf proto-oncogene, serine/threonine kinase

RET - REarranged during Transfection

MET - Metabolic Equivalent of Task

NTRK - Neurotrophic Tyrosine Receptor Kinase

HER2 - Human Epidermal Growth Factor Receptor 2